(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets - 2Vote in favor of Your Number one Cake Type
- 3Visual communication Programming for Fledglings
- 4'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
- 5How the Iran war may affect your money and bills
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Disability rights activist and author Alice Wong dies at 51
- Flu concerns grow in US as UK sees more cases among kids
- The Best Computer games for Multiplayer Fun
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- We may have one thing in common with jellyfish, new research finds
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Popular Film Areas: A Worldwide Manual for Film Enchantment
- Solid Living Tips: Experiences from a Wellness Fan
